New EAS Consensus Highlights Advances in Pediatric FH Care
European Atherosclerosis Society shared a post on LinkedIn about a recent article by Albert Wiegman et al., published in European Heart Journal։
“Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) concentrations, which increase the risk of premature atherosclerotic cardiovascular disease (ASCVD).
FH affects around 1 in 300 people worldwide, while the more severe form, Homozygous FH (HoFH), affects about 1 in 300,000 people and can lead to serious cardiovascular complications already in childhood.
Early diagnosis and treatment can dramatically improve – and even normalize – life expectancy.
Yet, fewer than 10% of affected children in Europe are currently identified.
The European Atherosclerosis Society (EAS) consensus statement on FH in children and adolescents highlights:
- Improved diagnostic criteria
- Earlier treatment initiation – sometimes from age 6
- Lower LDL-C treatment targets
- New lipid-lowering therapies
- Updated treatment algorithms
- Better transition from paediatric to adult care.
The statement emphasizes one key message: reducing lifelong exposure to high LDL-C is critical to protecting cardiovascular health from an early age.”
Title: Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement
Authors: Albert Wiegman, Mafalda Bourbon, Tomas Freiberger, Samuel S Gidding, Susanne Greber-Platzer, Urh Groselj, Kirsten B Holven, Lisa C Hudgins, Steve E Humphries, Barbara A Hutten, Daiana Ibarretxe, Cristina Pederiva, Noel Peretti, Frederick J Raal, Uma Ramaswami, Veronika Sanin, Raul D Santos, Elisabeth Steinhagen-Thiessen, Gerald F Watts, Rosie Perkins, Marianne Benn, Christoph J Binder, Stefano Romeo, Jeanine E Roeters van Lennep
Stay updated with Hemostasis Today.
-
Jul 5, 2026, 04:54Saneha Anjum Shaik: What Every Clinician Should Know Before Ordering Blood Tests
-
Jul 5, 2026, 04:37Mathis Richter: How The Bone Marrow Responds To Myocardial Infarction Predicts Clinical Outcome
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins